Daily News

November 26, 2019

• Asahi Kasei to Buy Veloxis for 143.2 Billion Yen, Eyes US Transplant Market
  November 26, 2019

• MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
  November 26, 2019

• MHLW Panel OKs Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor; 2 More Keytruda Usages Now in Line for Approval
  November 26, 2019

• Takeda Set to Pursue 4-Way Global Development, Hails China’s Market Potential
  November 26, 2019

• No Need for Acquisitions over Next 5 Years, 12 NMEs to Counter Patent Cliff: Takeda CEO
  November 26, 2019

• MHLW Panel Members Call for Need to “at Least Discuss” Whether to Resume Actively Recommending HPV Vaccines
  November 26, 2019

• Takeda’s ALK Drug Yield Positive Update in 1st Line NSCLC
  November 26, 2019

• Plaintiffs of HPV Vaccine Suits Prod JMA to Hear Stories of Victims
  November 26, 2019

• Xofluza Now Available in Taiwan: Shionogi
  November 26, 2019

• AnGes to Initiate US Clinical Study for Collategene in Arteriosclerosis Obliterans Patients with Lower Limb Ulcers
  November 26, 2019

• Asahi Kasei Pharma Licenses Fasudil to Woolsey; Development of Oral Formulation Expected
  November 26, 2019

• Keio Univ. Spin-Off Raises 2.8 Billion Yen to Develop Regenerative Medicine Products for Heart Failure
  November 26, 2019

• Mitsubishi Tanabe Kicks Off Multinational PIII of Edaravone Oral Suspension for ALS
  November 26, 2019

• Takeda’s Dengue Vaccine Demonstrates Consistent Efficacy in PIII
  November 26, 2019

• Sunovion Resubmits Sublingual Parkinson’s Drug in US
  November 26, 2019

• MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
  November 26, 2019